Cognitive decline covers a broad spectrum of disorders, not only resulting from brain
diseases but also from systemic diseases, which seriously influence the quality of life and …

Background The identification of biomarkers for the early diagnosis of Alzheimer's disease
(AD) is a crucial goal of the current research. Blood biomarkers are less invasive, easier to …

While cardiovascular disease, cancer, and human immunodeficiency virus (HIV) mortality
rates have decreased over the past 20 years, Alzheimer's Disease (AD) deaths have risen …

Numerous studies suggest that blood-brain barrier (BBB) dysfunction may contribute to the
progression of Alzheimer's disease (AD). Clinically available neuroimaging methods are …

Background Blood–brain barrier (BBB) dysfunction has been viewed as a potential
underlying mechanism of neurodegenerative disorders, possibly involved in the …

Background The impact of blood–brain barrier (BBB) leakage on white matter hyperintensity
(WMH) subtypes (location) and its association with clinical factors and cognition remains …

Tau protein is a critical driver of neurodegeneration and an important drug target in
Alzheimer's disease (AD). Tau-specific immunotherapy has emerged as a promising …

The blood-brain barrier (BBB) is a highly selective permeability barrier that safeguards the
central nervous system (CNS) from potentially harmful substances while regulating the …

Alzheimer's disease (AD) is a predominant and incurable chronic debilitating
neurodegenerative disorder occupying more than 60% of all types of dementias. It is …

Progress in Alzheimer's disease (AD) research is tightly linked to the availability of clinical
biomarkers to monitor the progression of the disease and provide mechanistic insight on the …